NCT04863313已完成不适用
Evaluation of the Effect of the Administration of a Probiotic Formulation on Glycemic Control, Insulin Resistance and the Composition of the Microbiota in Subjects With Prediabetes
Clinica Universidad de Navarra, Universidad de Navarra2 个研究点 分布在 1 个国家目标入组 73 人开始时间: 2021年3月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 73
- 试验地点
- 2
- 主要终点
- Change of blood glycated hemoglobin (HbA1c) concentration from baseline to week 12.
研究概览
简要总结
According to the data from the Di@bet.es study, which is part of the National Diabetes Strategy, the prevalence of type 2 diabetes among Spanish population is 13.8%. Diabetic patients suffer from several short and long term complications, which are related to a significant worsen of quality of life and a substantial increase in death rate.
In this sense, it is important to prevent the development of Type 2 diabetes. Therefore, it is of high relevance to identify and to treat prediabetic subjects prior to the development of the disease. Many strategies have been implemented to reverse this situation, such as changes in diet and lifestyle, among others. However, it is hard to achieve changes in lifestyle and despite the use of some drugs in this phase of the disease, the problem continues growing.
For this reason, new strategies to combat the development of type 2 diabetes are been investigated, such as the use of probiotic formulations. However, at the moment, few studies evidence the effect of probiotics on glycemic regulation. Therefore, an interesting opportunity arises according to the potential ability of probiotic formulation for the control of prediabetes.
Considering this background, the main objective of this research is to assess the effect of a new probiotic formulation on glycemic control, insulin resistance and the composition of the fecal microbiota in prediabetic subjects.
详细描述
This study is designed as a 12-week, double-blind, randomised, placebo-controlled parallel study. It is focused on prediabetic overweight / obese men and women between 18 and 70 years old.
All participants attend the Nutrition Intervention Unit of the Center for Nutrition Research in the University of Navarra for the screening visit and 4 more times during the intervention (week 1, 4, 8 and 12 of study).
- Screening visit: evaluation of the inclusion criteria.
Volunteers who meet the inclusion criteria are provided with a stool collection kit and a 72 h food record questionnaire. Moreover, they are randomly assigned to one of the two intervention groups:
Control group: placebo supplemented; Experimental group: probiotic supplemented.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men and women aged between 18 and 70 years.
- •Prediabetic subjects: glycosylated hemoglobin (HbA1c) between 5.7% and 6.4%.
- •Body Mass Index (BMI) between 25 and 39.9 kg / m
- •No weight changes (± 3 kg) during the last 3 months.
- •The subjects must be in general physical and psychological conditions in accordance with the objective of the study.
- •Subjects must be able to understand and sign the informed consent.
排除标准
- •To be in continuous pharmacological / hormonal treatment, especially those that could affect blood glucose concentration.
- •Suffering from a chronic metabolic disease, or from a systemic intestinal, liver or kidney disease: type 1 or 2 diabetes, severe dyslipidemia, uncontrolled thyroid function disorders, cirrhosis, inflammatory bowel disease, etc.
- •Subjects suffering from severe hyperlipidemia, severe hypertension or hypothyroidism without treatment or treated for less than 3 months.
- •Presence of relevant functional or structural abnormalities of the digestive system, such as malformations, angiodysplasia, active peptic ulcers, chronic inflammatory diseases or malabsorption.
- •Subjects who have undergone gastrointestinal surgery with permanent sequelae (for example, gastroduodenostomy).
- •Chronic treatment with stomach protectors.
- •Subjects suffering from some type of cancer or being in treatment for it or with a period less than 5 years since its eradication.
- •Presence of some type of mental impairment such as depressive pathology, anxiety or untreated bipolar disorder. They will be able to participate if they have stable treatment for at least 3 months prior to the begining of the trial.
- •Allergy or intolerance to any food or food group that is likely to manifest during the study.
- •Be on a special diet (Atkins, vegetarian, etc.) during the 3 months prior to the start of the study.
- •Weight variations (± 3 kg) during the last 3 months.
- •Suffering from eating disorders or eating restrictive behaviors (score on the EAT-26 questionnaire equal or greater than 20).
- •Subjects who have undergone surgical treatment for obesity.
- •Being pregnant or breastfeeding.
- •Abuse of alcohol (more than 14 units in women and 20 units in men) and / or drugs.
- •Show poor collaboration or, in the opinion of the investigator, have difficulties in following the study procedures.
- •Take some type of nutritional supplementation that can affect blood glucose and / or microbiota. If they take it, in order to be included in the study, they will have to stop the supplement, with a washout period of at least 14 days before starting the study.
- •People who are positive for Covid-19 will not be able to participate in the study.
结局指标
主要结局
Change of blood glycated hemoglobin (HbA1c) concentration from baseline to week 12.
时间窗: The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).
Fasting blood glycated hemoglobin (HbA1c) concentration will be reported in % and in mmol/mol.
次要结局
- Change of fasting blood glucose concentration from baseline to week 4.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 2 (after 4 weeks of intervention).)
- Change of fasting blood glucose concentration from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Oral glucose tolerance test(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of gastrointestinal symptoms from baseline to week 8.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 3 (after 8 weeks of intervention).)
- Change of gastrointestinal symptoms from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of blood ALT concentration from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of blood total cholesterol concentratio from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of blood triglyceride concentration from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of metagenomic analysis of intestinal microbiota composition from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of fasting blood glucose concentration from baseline to week 8.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 3 (after 8 weeks of intervention).)
- Change of HOMA index from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of Blood peptide-C concentration from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change in the Area under the curve for glucose from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of blood glucagon like peptide-1 (GLP-1) concentration from baseline to week 12.(The Time Frame contains two time points: day 1 (at baseline) compared to day 4 (after 12 weeks of intervention).)
- Change of gastrointestinal symptoms from baseline to week 4.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 2 (after 4 weeks of intervention).)
- Change of fasting blood insulin concentration from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of blood AST concentration from baseline to week 12.(The Time Frame contains two time points: day 1 (at baseline) compared to day 4 (after 12 weeks of intervention).)
- Change of blood HDL cholesterol concentration from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of blood LDL cholesterol concentration from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of hemogram from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of weight from baseline to week 4.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 2 (after 4 weeks of intervention).)
- Change of body mass index from baseline to week 4.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 2 (after 4 weeks of intervention).)
- Change of weight from baseline to week 8.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 3 (after 8 weeks of intervention).)
- Change of weight from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of body mass index from baseline to week 8.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 3 (after 8 weeks of intervention).)
- Change of waist circumference from baseline to week 4.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 2 (after 4 weeks of intervention).)
- Change of hip circumference from baseline to week 4.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 2 (after 4 weeks of intervention).)
- Change of hip circumference from baseline to week 8.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 3 (after 8 weeks of intervention).)
- Change of hip circumference from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of body composition (fat mass, lean mass and water content) from baseline to week 8.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 3 (after 8 weeks of intervention).)
- Change of systolic blood pressure from baseline to week 4.(The Time Frame contains two time points: day 1 (at baseline) compared to day 2 (after 4 weeks of intervention).)
- Change of systolic blood pressure from baseline to week 8.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 3 (after 8 weeks of intervention).)
- Change of systolic blood pressure from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of heart rate from baseline to week 4.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 2 (after 4 weeks of intervention).)
- Change of body mass index from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of waist circumference from baseline to week 8.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 3 (after 8 weeks of intervention).)
- Change of waist circumference from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of body composition (fat mass, lean mass and water content) from baseline to week 4.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 2 (after 4 weeks of intervention).)
- Change of body composition (fat mass, lean mass and water content) from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of dyastolic blood pressure from baseline to week 8.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 3 (after 8 weeks of intervention).)
- Adherence to the intervention at week 4.(Clinical investigation day 2 (week 4).)
- Change of dyastolic blood pressure from baseline to week 4.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 2 (after 4 weeks of intervention).)
- Change of dyastolic blood pressure from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of heart rate from baseline to week 8.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 3 (after 8 weeks of intervention).)
- Change of heart rate from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change of physical activity from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Change on food intake from baseline to week 12.(The Time Frame contains two time points: Clinical Investigation Day 1 (at baseline) compared to Clinical Investigation Day 4 (after 12 weeks of intervention).)
- Adherence to the intervention at week 8.(Clinical investigation day 3 (week 8).)
- Adherence to the intervention at week 12.(Clinical investigation day 4 (week 12).)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Evaluating the effectiveness of a Diabetes Needs Assessment Tool (DNAT): a randomised controlled trialDiabetesISRCTN67215088BMJ Group (UK)200
已完成
不适用
Observational Study Describing Conditions for Intensification of Insulin Therapy in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00712478Novo Nordisk A/S114
已完成
不适用
Diabetes prevention study in Hindustani SurinameseImpaired fasting glucose (IFG), impaired glucose tolerance (IGT) and Diabetes Mellitus type 2 (DM type II)NL-OMON29212Academic Medical Centre (AMC), Dept. of Social Medicine500
已完成
不适用
The development of a successful group-based lifestyle modification program for chronic disease, such as type 2 diabetes.Metabolic and Endocrine - DiabetesType 2 DiabetesACTRN12614000572662Bond University90
已完成
不适用
Effectiveness and Cost-effectiveness of the Diabetes Integrated Care Breakthrough CollaborativeDiabetes Mellitus, Non-Insulin-DependentNCT00160017Radboud University Medical Center1,861